ATE526421T1 - Verfahren und reagenzien zur behandlung und diagnose von altersbedingter makuladegeneration - Google Patents

Verfahren und reagenzien zur behandlung und diagnose von altersbedingter makuladegeneration

Info

Publication number
ATE526421T1
ATE526421T1 AT06735123T AT06735123T ATE526421T1 AT E526421 T1 ATE526421 T1 AT E526421T1 AT 06735123 T AT06735123 T AT 06735123T AT 06735123 T AT06735123 T AT 06735123T AT E526421 T1 ATE526421 T1 AT E526421T1
Authority
AT
Austria
Prior art keywords
reagents
diagnosis
treatment
age
methods
Prior art date
Application number
AT06735123T
Other languages
English (en)
Inventor
Gregory S Hageman
Original Assignee
Univ Iowa Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36917017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE526421(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Iowa Res Found filed Critical Univ Iowa Res Found
Application granted granted Critical
Publication of ATE526421T1 publication Critical patent/ATE526421T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT06735123T 2005-02-14 2006-02-14 Verfahren und reagenzien zur behandlung und diagnose von altersbedingter makuladegeneration ATE526421T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US65307805P 2005-02-14 2005-02-14
US71550305P 2005-09-09 2005-09-09
US71786105P 2005-09-16 2005-09-16
US73569705P 2005-11-09 2005-11-09
PCT/US2006/005313 WO2006088950A2 (en) 2005-02-14 2006-02-14 Methods and reagents for treatment and diagnosis of age-related macular degeneration

Publications (1)

Publication Number Publication Date
ATE526421T1 true ATE526421T1 (de) 2011-10-15

Family

ID=36917017

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06735123T ATE526421T1 (de) 2005-02-14 2006-02-14 Verfahren und reagenzien zur behandlung und diagnose von altersbedingter makuladegeneration

Country Status (12)

Country Link
US (8) US8088579B2 (de)
EP (5) EP2302076B1 (de)
JP (4) JP2008529536A (de)
KR (2) KR20130100207A (de)
CN (1) CN103920142A (de)
AT (1) ATE526421T1 (de)
AU (1) AU2006214320C1 (de)
CA (1) CA2597411C (de)
IL (2) IL185219A (de)
MX (1) MX2007009565A (de)
NZ (2) NZ595305A (de)
WO (1) WO2006088950A2 (de)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0506629A (pt) * 2004-02-10 2007-05-02 Univ Colorado inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
BRPI0518289A2 (pt) * 2004-11-18 2008-11-11 Univ Yale mÉtodos e composiÇÕes para o tratamento de desordens oculares
CA2597411C (en) * 2005-02-14 2014-08-12 University Of Iowa Research Foundation Use of complement factor h polymorphisms in treatment and diagnosis of age-related macular degeneration
WO2006096561A2 (en) 2005-03-04 2006-09-14 Duke University Genetic variants increase the risk of age-related macular degeneration
US20070037183A1 (en) * 2005-03-07 2007-02-15 Trustees Of Boston University Diagnostic and therapeutic target for macular degeneration
JP5707024B2 (ja) * 2005-05-26 2015-04-22 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ 外傷性脳損傷、脊髄損傷および関連状態を治療するために補体副経路を阻害する作用剤
EP1937706A4 (de) * 2005-09-09 2008-10-22 Univ Iowa Res Found Mit altersabhängiger makulardegeneration in zusammenhang stehende biologische marker
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
HUE026423T2 (en) * 2005-11-04 2016-05-30 Genentech Inc Use of complement biosynthetic pathway inhibitors for treating eye diseases
AU2006330501B2 (en) * 2005-12-22 2012-04-05 Alcon Research, Ltd. C3-convertase inhibitors for the prevention and treatment of age-related macular degeneration in patients with at risk variants of complement factor H
US20080146501A1 (en) * 2006-02-13 2008-06-19 University Of Iowa Research Foundation Protective complement proteins and age-related macular degeneration
WO2007120975A2 (en) 2006-02-13 2007-10-25 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Variants in complement regulatory genes predict age-related macular degeneration
US8012683B2 (en) 2006-02-13 2011-09-06 University Of Iowa Research Foundation Variants in complement regulatory genes predict age-related macular degeneration
GB0611606D0 (en) * 2006-06-13 2006-07-19 Univ Belfast Protection against and treatment of age related macular degeneration
EP2044111B1 (de) 2006-06-21 2014-08-13 MUSC Foundation For Research Development Targeting des komplement-faktors h zur krankheitsbehandlung
JP5431151B2 (ja) 2006-07-13 2014-03-05 ユニバーシティー オブ アイオワ リサーチ ファンデーション 血管障害および加齢黄斑変性症の治療および診断のための方法および試薬
MX2009000909A (es) * 2006-07-26 2009-02-04 Univ Yale Diagnostico y tratamiento de degeneracion macular relacionada con la edad.
CA2661161A1 (en) * 2006-08-23 2008-02-28 University Of Iowa Research Foundation Biomarkers associated with age-related macular degeneration
SI2097455T1 (sl) 2006-11-02 2015-03-31 Genentech, Inc. Humanizirana protitelesa proti faktorju tipa d
GB0701213D0 (en) 2007-01-23 2007-02-28 Univ Cardiff Factor H polymorphisms in the diagnosis and therapy of inflammatory diseases such as age-related macular degeneration
WO2008103299A2 (en) 2007-02-16 2008-08-28 Massachusetts Eye & Ear Infirmary Methods and compositions for prognosing, detecting, and treating age-related macular degeneration
WO2008110828A1 (en) * 2007-03-14 2008-09-18 Dsm Ip Assets B.V. Method for prevention of age-related macular degeneration (amd)
EP2565207A3 (de) * 2007-03-14 2013-06-12 Alexion Cambridge Corporation Humanisierte Anti-Faktor-B-Antikörper
WO2008110283A2 (en) * 2007-03-14 2008-09-18 Dsm Ip Assets B.V. Method for prevention of age-related macular degeneration (amd)
EP2139471A2 (de) * 2007-04-30 2010-01-06 Alcon Research, Ltd. Behandlung von altersbedingter makula-degeneration mit hemmern des komplement-faktors d
AU2008251801A1 (en) * 2007-05-11 2008-11-20 The General Hospital Corporation Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk
WO2009029587A2 (en) * 2007-08-24 2009-03-05 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating macular degeneration
US20100303832A1 (en) * 2007-11-01 2010-12-02 Hageman Gregory S Genes and polymorphisms associated with amd
CA2721503A1 (en) * 2008-04-18 2009-12-03 Massachusetts General Hospital Polymorphisms associated with age-related macular degeneration and methods for evaluating patient risk
WO2009134709A2 (en) * 2008-04-28 2009-11-05 Tufts Medical Center Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
DE102008049136B4 (de) * 2008-09-26 2012-10-25 Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. Neue Regulatoren des angeborenen Immunsystems
US20100145223A1 (en) * 2008-11-26 2010-06-10 Duke University Peripheral Reticular Pigmentary Change and Age-Related Macular Degeneration
GB0904427D0 (en) 2009-03-13 2009-04-29 Lachmann Peter Treatment of diseases related to hyperactivity of the complement system
RS20120461A1 (sr) 2009-07-02 2013-06-28 Musc Foundation For Research Development Metode za stimulaciju regeneracije jetre
GB0911717D0 (en) * 2009-07-06 2009-08-19 Ucl Business Plc Method
CA2781595C (en) 2009-07-10 2016-07-05 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating macular degeneration
KR20120049267A (ko) * 2009-07-16 2012-05-16 글락소 웰컴 매뉴팩쳐링 피티이 엘티디 치료 방법
AT516600B1 (de) * 2009-07-23 2016-07-15 Baxter Int Herstellung von faktor h (fh) und fh-derivaten aus plasma
US8236570B2 (en) * 2009-11-03 2012-08-07 Infoscitex Methods for identifying nucleic acid ligands
NZ600393A (en) 2009-11-05 2014-08-29 Alexion Cambridge Corp Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
FR2952539B1 (fr) * 2009-11-16 2012-01-13 Lab Francais Du Fractionnement Preparation d'un concentre de facteur h
GB0922659D0 (en) 2009-12-24 2010-02-10 Univ Edinburgh Factor H
US20130011857A1 (en) 2010-02-12 2013-01-10 Cemm Forschungszentrum Fur Molekulare Medizin Gmbh Complement factor h for oxidative stress disease conditions
EP2569446B1 (de) * 2010-05-12 2018-07-11 Steven E. Schutzer Diagnostische marker für neuropsychiatrische erkrankungen
MX2012013233A (es) 2010-05-14 2013-05-20 Univ Colorado Regents Grupos que apuntan a receptor 2 de complemento (cr2) mejorados.
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US8796430B2 (en) 2010-05-26 2014-08-05 Baxter International Inc. Method to produce an immunoglobulin preparation with improved yield
US9421240B2 (en) 2010-06-22 2016-08-23 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
CN103249432A (zh) 2010-06-22 2013-08-14 科罗拉多大学董事会,法人团体 补体成分3的C3d片段的抗体
CA2814066A1 (en) * 2010-10-14 2012-04-19 Sequenom, Inc. Complement factor h copy number variants found in the rca locus
SG190078A1 (en) * 2010-11-01 2013-06-28 Genentech Inc Predicting progression to advanced age-related macular degeneration using a polygenic score
WO2012112955A2 (en) 2011-02-17 2012-08-23 The Trustees Of Columbia University In The City Of New York Methods for identifying subjects with a genetic risk for developing iga nephropathy
CN103874526A (zh) * 2011-04-29 2014-06-18 犹他大学研究基金会 预测补体介导的疾病的发展的方法
FR2988298A1 (fr) * 2012-03-23 2013-09-27 Lfb Biotechnologies Facteur h pour son utilisation comme molecule antioxydante
WO2013177035A2 (en) 2012-05-24 2013-11-28 Alexion Pharmaceuticals, Inc. Humaneered anti-factor b antibody
US20140004105A1 (en) * 2012-06-29 2014-01-02 Sequenom, Inc. Age-related macular degeneration diagnostics
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
US20150211065A1 (en) * 2012-09-14 2015-07-30 University Of Utah Research Foundation Methods of predicting the development of amd based on chromosome 1 and chromosome 10
ES2780674T3 (es) 2012-11-15 2020-08-26 Apellis Pharmaceuticals Inc Análogos de compstatina de acción prolongada y composiciones y métodos relacionados
GB201301632D0 (en) * 2013-01-30 2013-03-13 Imp Innovations Complement System
CA2908597A1 (en) * 2013-03-14 2014-09-25 Baxalta Incorporated Factor h for treatment of rheumatoid arthritis
PT2968457T (pt) 2013-03-14 2018-11-07 Baxalta Inc Fator h para transplante
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
AU2013202965B2 (en) 2013-03-15 2016-07-21 Takeda Pharmaceutical Company Limited Improved method for producing factor h from a plasma precipitation fraction
WO2014169294A1 (en) 2013-04-12 2014-10-16 The Trustees Of Columbia University In The City Of New York Mutations in dstyk cause dominant urinary tract malformations
US10183988B2 (en) 2013-06-07 2019-01-22 Duke University Anti-Complement factor H antibodies
CA2920666A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. Compositions and method for treating complement-associated conditions
US9977036B2 (en) 2013-08-15 2018-05-22 Steven E. Schutzer Diagnostic markers for multiple sclerosis
EP3033093A1 (de) 2013-08-16 2016-06-22 Alexion Pharmaceuticals, Inc. Behandlung von transplantatabstossung durch verabreichung eines komplementinhibitors an ein organ vor der transplantation
US10155983B2 (en) 2014-03-31 2018-12-18 Machaon Diagnostics, Inc. Method of diagnosis of complement-mediated thrombotic microangiopathies
CR20160561A (es) 2014-05-01 2017-05-03 Genentech Inc Variantes del anticuerpo anti-factor d y sus usos
US10672505B2 (en) 2015-06-03 2020-06-02 General Electric Company Biological data annotation and visualization
US9953133B2 (en) 2015-06-03 2018-04-24 General Electric Company Biological data annotation and visualization
US9607375B2 (en) * 2015-06-03 2017-03-28 Eileen B. Gallagher Biological data annotation and visualization
US10988519B2 (en) 2015-09-24 2021-04-27 The Trustees Of The University Of Pennsylvania Composition and method for treating complement-mediated disease
FI3359555T3 (fi) 2015-10-07 2024-03-20 Apellis Pharmaceuticals Inc Annostusohjeet
GB201519086D0 (en) * 2015-10-28 2015-12-09 Syncona Partners Llp Gene Therapy
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
US10654932B2 (en) 2015-10-30 2020-05-19 Genentech, Inc. Anti-factor D antibody variant conjugates and uses thereof
WO2017109164A1 (en) 2015-12-23 2017-06-29 Université Pierre Et Marie Curie - Paris 6 (Upmc) AGENTS THAT INHIBIT THE BINDING OF CFH TO CD11b/CD18 AND USES THEREOF
FR3046355A1 (fr) * 2015-12-30 2017-07-07 Lab Francais Du Fractionnement Fragments du facteur h pour son utilisation comme agent anti-angiogenique
CN109476637B (zh) 2016-06-21 2022-02-01 奥瑞恩眼科有限责任公司 杂环脯氨酰胺衍生物
AU2017384348B2 (en) * 2016-12-22 2024-03-07 Daiichi Sankyo Company, Limited Peptide for treating age-related macular degeneration
US11040107B2 (en) 2017-04-07 2021-06-22 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
CN111788311A (zh) * 2017-10-20 2020-10-16 双子治疗公司 用于治疗年龄相关性黄斑变性的组合物和方法
WO2019118938A1 (en) 2017-12-15 2019-06-20 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
CA3100995A1 (en) * 2018-05-10 2019-11-14 The University Of Manchester Methods for assessing macular degeneration
US20210338838A1 (en) * 2018-07-20 2021-11-04 University Of Utah Research Foundation Gene therapy for macular degeneration
CN112969367B (zh) * 2018-09-13 2023-04-07 瑞泽恩制药公司 作为c3肾小球病模型的补体因子h基因敲除大鼠
GB201821089D0 (en) * 2018-12-21 2019-02-06 Gyroscope Therapeutics Ltd Codon-optimised complement factor I
WO2021081203A1 (en) * 2019-10-22 2021-04-29 Applied Genetic Technologies Corporation Adeno-associated virus (aav)vectors for the treatment of age-related macular degeneration and other ocular diseases and disorders
JP2023529497A (ja) 2020-06-14 2023-07-10 バーテックス ファーマシューティカルズ インコーポレイテッド 補体因子ｉ関連組成物および方法
JP2023537814A (ja) 2020-06-19 2023-09-06 エンドジーナ セラペウティクス インコーポレーテッド 網膜色素上皮に関与する疾患の治療及び／又は予防における治療活性物質としての新規化合物及びそれらの使用
GB202010009D0 (en) * 2020-06-30 2020-08-12 Syncona Investment Man Ltd Vector
US11541039B2 (en) 2020-10-08 2023-01-03 Endogena Therapeutics, Inc. Compounds and their use as therapeutically active substances in the treatment and/or reducing signs or symptoms of diseases involving the retinal pigment epithelium
GB202107586D0 (en) 2021-05-27 2021-07-14 Complement Therapeutics Ltd Inhibitory nucleic acids for Factor H family proteins
LU103244B1 (en) 2024-02-14 2025-08-14 Univ Hamburg Eppendorf Uke Deletion of the mouse homolog of human FHR1 (FHRE) protects ApoE-/- mice from atherosclerosis

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0742235B2 (ja) 1985-11-08 1995-05-10 三共株式会社 自己免疫性疾病の予防・治療剤
NO870613L (no) 1986-03-05 1987-09-07 Molecular Diagnostics Inc Deteksjon av mikroorganismer i en prŸve inneholdende nukleinsyre.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US5037746A (en) 1986-12-03 1991-08-06 University Patents, Inc. RNA ribozyme polymerases, and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
EP0832981A1 (de) 1987-02-17 1998-04-01 Pharming B.V. DNA-Sequenzen die Proteine zwecks effizienter Abscheidung zur Milchdrüse leiten
DE68928853T2 (de) 1988-05-20 1999-08-05 Cetus Corp., Emeryville, Calif. Befestigung von sequenzspezifischen proben
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5180818A (en) 1990-03-21 1993-01-19 The University Of Colorado Foundation, Inc. Site specific cleavage of single-stranded dna
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
CA2084307A1 (en) 1990-06-01 1991-12-02 Cetus Oncology Corporation Compositions and methods for identifying biologically active molecules
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0940468A1 (de) 1991-06-14 1999-09-08 Genentech, Inc. Änderliches Gebiet einer humanisierter Antikörper
US5770358A (en) 1991-09-18 1998-06-23 Affymax Technologies N.V. Tagged synthetic oligomer libraries
ATE198358T1 (de) 1992-04-27 2001-01-15 Dartmouth College Detektion von gensequenzen in biologischen flüssigkeiten
DE4222534A1 (de) 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
DE69333087T2 (de) 1992-10-01 2004-05-06 The Trustees Of Columbia University In The City Of New York Komplexe kombinatorische chemische banken, die mit markierungen versehen sind
ATE312188T1 (de) 1993-01-22 2005-12-15 Univ Research Corp Lokalisierung von therapeutischen mitteln
NZ276860A (en) 1993-11-02 1997-09-22 Affymax Tech Nv Apparatus and its use for synthesising diverse molecular products on substrates
US5667969A (en) 1993-11-12 1997-09-16 University Research Corporation Alteration of sequence of a deleterious target molecule by ribozyme catalyzed trans-splicing
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
CA2189634A1 (en) 1994-05-06 1995-11-16 John J. Baldwin Combinatorial dihydrobenzopyran library
US5663046A (en) 1994-06-22 1997-09-02 Pharmacopeia, Inc. Synthesis of combinatorial libraries
US5959171A (en) 1994-08-17 1999-09-28 Pharming B.V. Method for the production of biologically active polypeptides in a mammal's
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US6706471B1 (en) 1996-01-24 2004-03-16 Third Wave Technologies, Inc. Detection of nucleic acid sequences by invader-directed cleavage
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US6969601B2 (en) * 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
GB9710475D0 (en) 1997-05-21 1997-07-16 Zeneca Ltd Gene silencing
US8007798B2 (en) * 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
EP2267138B1 (de) 1998-04-08 2016-06-08 Commonwealth Scientific and Industrial Research Organization Verfahren und Mittel zum Erhalt von modifizierten Phänotypen
US7312050B2 (en) 1998-10-29 2007-12-25 University Of Iowa Research Foundation Nucleic acids encoding interphotoreceptor matrix proteins
EP2314700A1 (de) 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Zusammensetzung und Verfahren zur in vivo und in vitro Abschwächung der Genexpression mittels dobbelsträngiger RNA
US7108982B1 (en) 1999-02-19 2006-09-19 University Of Iowa Research Foundation Diagnostics and the therapeutics for macular degeneration
US20020102581A1 (en) 1999-02-19 2002-08-01 Hageman Gregory S. Diagnostics and therapeutics for ocular disorders
ATE343792T1 (de) * 1999-02-19 2006-11-15 Univ Iowa Res Found Diagnostika und therapeutika für maculare degeneration
EP1161686A2 (de) * 1999-03-05 2001-12-12 University Of Iowa Research Foundation Diagnostika und therapeutika für mit drusen assozierten augenbeschwerden
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US7011952B2 (en) 2000-02-22 2006-03-14 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
PT1309726E (pt) 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
WO2001084149A2 (en) 2000-04-29 2001-11-08 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
US6632606B1 (en) 2000-06-12 2003-10-14 Aclara Biosciences, Inc. Methods for single nucleotide polymorphism detection
KR100909681B1 (ko) 2000-12-01 2009-07-29 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
CN1364780A (zh) * 2001-01-10 2002-08-21 上海博德基因开发有限公司 一种新的多肽——补体因子h12.32和编码这种多肽的多核苷酸
WO2002081638A2 (en) * 2001-04-06 2002-10-17 Origene Technologies, Inc Prostate cancer expression profiles
US20060241074A1 (en) 2001-08-14 2006-10-26 The General Hospital Corporation Methods for treatment of pain
ATE427356T1 (de) 2003-06-02 2009-04-15 Varleigh Ltd Komplementinhibitoren aus zecken
WO2005014849A2 (en) 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
WO2005003159A1 (en) 2003-07-03 2005-01-13 Koeln Johanna Complement depletion using recombinant human c3-derivatives
US7300471B2 (en) 2004-02-27 2007-11-27 L'oreal S.A. Composition comprising at least one mixed dye based on at least one chromophore of azo or tri(hetero) arylmethane type, dyeing process and mixed dyes.
PL2465534T3 (pl) * 2004-06-10 2017-08-31 Omeros Corporation Sposoby leczenia stanów związanych z aktywacją dopełniacza zależną od masp-2
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20060018896A1 (en) * 2004-06-10 2006-01-26 University Of Leicester Methods for treating conditions associated with lectin-dependent complement activation
BRPI0518289A2 (pt) * 2004-11-18 2008-11-11 Univ Yale mÉtodos e composiÇÕes para o tratamento de desordens oculares
CA2597411C (en) 2005-02-14 2014-08-12 University Of Iowa Research Foundation Use of complement factor h polymorphisms in treatment and diagnosis of age-related macular degeneration
US8101169B2 (en) 2005-02-23 2012-01-24 The Board Of Trustees Of The Leland Stanford Junior University Ocular gene therapy using avalanche-mediated transfection
WO2006096561A2 (en) 2005-03-04 2006-09-14 Duke University Genetic variants increase the risk of age-related macular degeneration
US20070037183A1 (en) 2005-03-07 2007-02-15 Trustees Of Boston University Diagnostic and therapeutic target for macular degeneration
NZ565659A (en) 2005-06-08 2010-03-26 Univ Pittsburgh Susceptibility genes for age-related maculopathy (ARM) on chromosome 10Q26
WO2007022590A1 (en) 2005-08-24 2007-03-01 Genetic Technologies Limited Identification of ancestral haplotypes and uses thereof
EP1937706A4 (de) * 2005-09-09 2008-10-22 Univ Iowa Res Found Mit altersabhängiger makulardegeneration in zusammenhang stehende biologische marker
US8012683B2 (en) * 2006-02-13 2011-09-06 University Of Iowa Research Foundation Variants in complement regulatory genes predict age-related macular degeneration
US20080146501A1 (en) 2006-02-13 2008-06-19 University Of Iowa Research Foundation Protective complement proteins and age-related macular degeneration
JP5431151B2 (ja) * 2006-07-13 2014-03-05 ユニバーシティー オブ アイオワ リサーチ ファンデーション 血管障害および加齢黄斑変性症の治療および診断のための方法および試薬
CA2661161A1 (en) * 2006-08-23 2008-02-28 University Of Iowa Research Foundation Biomarkers associated with age-related macular degeneration
US20100303832A1 (en) * 2007-11-01 2010-12-02 Hageman Gregory S Genes and polymorphisms associated with amd
US7952830B2 (en) * 2009-06-04 2011-05-31 Samsung Electronics Co., Ltd. Method and apparatus for estimating flying height in a hard disk drive

Also Published As

Publication number Publication date
US7745389B2 (en) 2010-06-29
AU2006214320A1 (en) 2006-08-24
CN103920142A (zh) 2014-07-16
US20160096871A1 (en) 2016-04-07
US8088579B2 (en) 2012-01-03
EP2357257B1 (de) 2019-07-31
CA2597411A1 (en) 2006-08-24
KR20130100207A (ko) 2013-09-09
US20200165307A1 (en) 2020-05-28
AU2006214320C1 (en) 2012-07-05
IL185219A (en) 2013-11-28
US20090124542A1 (en) 2009-05-14
NZ595305A (en) 2013-06-28
EP2302076B1 (de) 2014-11-12
US20090247451A1 (en) 2009-10-01
EP2357254A1 (de) 2011-08-17
EP1856287A2 (de) 2007-11-21
HK1113176A1 (en) 2008-09-26
EP2377951A1 (de) 2011-10-19
IL225203A (en) 2015-07-30
US20170369543A1 (en) 2017-12-28
CA2597411C (en) 2014-08-12
IL185219A0 (en) 2008-02-09
US20130296255A1 (en) 2013-11-07
WO2006088950A3 (en) 2006-12-28
US11168120B2 (en) 2021-11-09
JP2012254089A (ja) 2012-12-27
EP2357257A1 (de) 2011-08-17
JP2008529536A (ja) 2008-08-07
US20090258822A1 (en) 2009-10-15
EP1856287B1 (de) 2011-09-28
JP2012139228A (ja) 2012-07-26
HK1154634A1 (en) 2012-04-27
EP2302076A1 (de) 2011-03-30
WO2006088950A2 (en) 2006-08-24
US20070020647A1 (en) 2007-01-25
JP2014204729A (ja) 2014-10-30
AU2006214320B2 (en) 2011-07-07
WO2006088950B1 (en) 2007-03-01
NZ608860A (en) 2014-10-31
JP5100901B2 (ja) 2012-12-19
MX2007009565A (es) 2008-03-10
US8497350B2 (en) 2013-07-30
KR20070112801A (ko) 2007-11-27

Similar Documents

Publication Publication Date Title
ATE526421T1 (de) Verfahren und reagenzien zur behandlung und diagnose von altersbedingter makuladegeneration
WO2008137236A3 (en) Treatment of age-related macular degeneration using inhibitors of complement factor d
ATE528410T1 (de) Verfahren und zusammensetzungen zur diagnose von altersbedingter maculadegeneration
DE602006018583D1 (de) Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
ATE488251T1 (de) Verfahren zur diagnose und behandlung von schwangerschaftsskomplikationen
DE602006018354D1 (de) Verfahren zur behandlung von abnormalem zellwachstum
EP1877175A4 (de) Vorrichtung und verfahren zur herstellung von radiopharmazeutika
EP1916964A4 (de) Implantate und verfahren zur behebung, ersetzung und behandlung von gelenkkrankheiten
DE602006019753D1 (de) Verfahren und gerät zur behandlung von aneurysmen der a. thoracica
DE112005002742A5 (de) Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreasererkrankungen
EP1896083A4 (de) Verfahren zur behandlung von pompe-krankheit mit 1-desoxynojirimycin und derivaten
ATE536177T1 (de) Calixaren-basierte peptidkonformationsmimetika, verfahren zu ihrer verwendung und verfahren zu ihrer herstellung
EP1991274A4 (de) Verfahren zur behandlung, prophylaxe und diagnose von knochenerkrankungen
DE602005014134D1 (de) Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten
ATE515700T1 (de) Blutgruppenantigene verschiedener typen für diagnostische und therapeutische anwendungen
ATE519503T1 (de) Verfahren zur behandlung von patienten mit hepatitis c
DE602005019247D1 (de) Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen
ATE406801T1 (de) Verfahren zur herstellung von sauermilchprodukten
EP2046366A4 (de) Verfahren zur behandlung von altersbedingter makuladegeneration
DE602004021847D1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
DE602006017995D1 (de) Verfahren zur herstellung von pregabalin und salzen daraus
EP1869212A4 (de) Verwendung von id4 zur diagnose und behandlung von krebs
EP1689347A4 (de) Verfahren und reagenzien zur behandlund prävention und diagnose von bunyavirus infektion
WO2007076437A3 (en) C3-convertase inhibitors for the prevention and treatment of age-related macular degeneration in patients with at risk variants of complement factor h
ATE516290T1 (de) Verfahren zur herstellung von buprenorphin und derivaten von buprenorphin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties